SG11201811543XA - Rotigotine behenate, and manufacturing method and application thereof - Google Patents
Rotigotine behenate, and manufacturing method and application thereofInfo
- Publication number
- SG11201811543XA SG11201811543XA SG11201811543XA SG11201811543XA SG11201811543XA SG 11201811543X A SG11201811543X A SG 11201811543XA SG 11201811543X A SG11201811543X A SG 11201811543XA SG 11201811543X A SG11201811543X A SG 11201811543XA SG 11201811543X A SG11201811543X A SG 11201811543XA
- Authority
- SG
- Singapore
- Prior art keywords
- rotigotine behenate
- manufacturing
- application
- rotigotine
- behenate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/08—Hydrogen atoms or radicals containing only hydrogen and carbon atoms
- C07D333/10—Thiophene
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
Rotigotine Behenate, and Manufacturing Method and Application thereof The present invention relates to a rotigotine behenate and a manufacturing method and application thereof, and provides a method for manufacturing the rotigotine behenate and an application of the rotigotine behenate in treating a disease related to a dopamine receptor. The structure of the rotigotine behenate is represented by formula I. The fluctuations of plasma concentration of the rotigotine behenate in vivo are small. The rotigotine behenate can maintain an effective plasma concentration for an extended period, has high bioavailability, and can achieve the effect of extended, effective, and stable release. I
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2016/090803 WO2018014277A1 (en) | 2016-07-21 | 2016-07-21 | Rotigotine behenate, and manufacturing method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811543XA true SG11201811543XA (en) | 2019-02-27 |
Family
ID=60992805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811543XA SG11201811543XA (en) | 2016-07-21 | 2016-07-21 | Rotigotine behenate, and manufacturing method and application thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10669249B2 (en) |
| EP (1) | EP3489227B1 (en) |
| JP (1) | JP6751208B2 (en) |
| KR (1) | KR20190031314A (en) |
| CN (1) | CN109415335B (en) |
| AU (1) | AU2016415408B2 (en) |
| BR (1) | BR112019001035A2 (en) |
| CA (1) | CA3030043C (en) |
| ES (1) | ES2855976T3 (en) |
| MY (1) | MY195897A (en) |
| PH (1) | PH12018550212A1 (en) |
| PL (1) | PL3489227T3 (en) |
| RU (1) | RU2717542C9 (en) |
| SG (1) | SG11201811543XA (en) |
| WO (1) | WO2018014277A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3489227B1 (en) * | 2016-07-21 | 2020-10-21 | Shandong Luye Pharmaceutical Co., Ltd. | Rotigotine behenate, and manufacturing method and application thereof |
| CN108341798B (en) * | 2017-01-23 | 2021-05-25 | 沈阳药科大学 | Rotigotine derivative and preparation and application thereof |
| WO2021063347A1 (en) | 2019-09-30 | 2021-04-08 | 山东绿叶制药有限公司 | Compound and preparation method therefor and use thereof |
| EP4238966A4 (en) | 2020-10-27 | 2024-05-15 | Guangzhou Henovcom Bioscience Co. Ltd. | Tetrahydronaphthalene compound, pharmaceutical composition thereof, and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1426049B1 (en) * | 2002-12-02 | 2005-05-18 | Schwarz Pharma Ag | Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease |
| DE10361259A1 (en) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Use of Rotigotine in Early Stage Parkinson's Disease to Prevent Further Neuronal Loss |
| RU2589700C2 (en) * | 2010-11-25 | 2016-07-10 | Шан Донг Люие Фармацеутикал Ко., Лтд | Rotigotine compositions, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or derivatives thereof |
| WO2013168033A1 (en) * | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
| US9956201B2 (en) * | 2014-07-21 | 2018-05-01 | Spriaso Llc | Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms |
| WO2016014242A1 (en) * | 2014-07-21 | 2016-01-28 | Spriaso Llc | Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods |
| EP3489227B1 (en) * | 2016-07-21 | 2020-10-21 | Shandong Luye Pharmaceutical Co., Ltd. | Rotigotine behenate, and manufacturing method and application thereof |
-
2016
- 2016-07-21 EP EP16909205.3A patent/EP3489227B1/en active Active
- 2016-07-21 KR KR1020197005257A patent/KR20190031314A/en active IP Right Grant
- 2016-07-21 RU RU2018146096A patent/RU2717542C9/en active
- 2016-07-21 ES ES16909205T patent/ES2855976T3/en active Active
- 2016-07-21 BR BR112019001035-1A patent/BR112019001035A2/en not_active IP Right Cessation
- 2016-07-21 AU AU2016415408A patent/AU2016415408B2/en active Active
- 2016-07-21 CA CA3030043A patent/CA3030043C/en not_active Expired - Fee Related
- 2016-07-21 WO PCT/CN2016/090803 patent/WO2018014277A1/en unknown
- 2016-07-21 MY MYPI2018002909A patent/MY195897A/en unknown
- 2016-07-21 PL PL16909205T patent/PL3489227T3/en unknown
- 2016-07-21 JP JP2019524492A patent/JP6751208B2/en active Active
- 2016-07-21 SG SG11201811543XA patent/SG11201811543XA/en unknown
- 2016-07-21 CN CN201680087177.7A patent/CN109415335B/en active Active
- 2016-07-21 US US16/309,807 patent/US10669249B2/en active Active
-
2018
- 2018-12-26 PH PH12018550212A patent/PH12018550212A1/en unknown
-
2020
- 2020-04-27 US US16/860,037 patent/US11111227B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2717542C1 (en) | 2020-03-24 |
| PH12018550212A1 (en) | 2019-10-28 |
| PL3489227T3 (en) | 2021-05-04 |
| AU2016415408A1 (en) | 2019-01-17 |
| CA3030043C (en) | 2021-01-19 |
| BR112019001035A2 (en) | 2019-04-30 |
| US11111227B2 (en) | 2021-09-07 |
| AU2016415408B2 (en) | 2019-04-11 |
| ES2855976T3 (en) | 2021-09-27 |
| EP3489227A4 (en) | 2020-01-22 |
| EP3489227B1 (en) | 2020-10-21 |
| CN109415335A (en) | 2019-03-01 |
| EP3489227A1 (en) | 2019-05-29 |
| US20190330177A1 (en) | 2019-10-31 |
| MY195897A (en) | 2023-02-27 |
| JP2019523297A (en) | 2019-08-22 |
| KR20190031314A (en) | 2019-03-25 |
| RU2717542C9 (en) | 2020-08-12 |
| US10669249B2 (en) | 2020-06-02 |
| CN109415335B (en) | 2020-06-05 |
| US20200255396A1 (en) | 2020-08-13 |
| CA3030043A1 (en) | 2018-01-25 |
| JP6751208B2 (en) | 2020-09-02 |
| WO2018014277A1 (en) | 2018-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018550212A1 (en) | Rotigotine behenate and preparation method and use thereof | |
| CR20140161A (en) | BENZILINDAZOLS REPLACED FOR USE AS INHIBITORS OF QUINASA BUB1 IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | |
| EA201590583A1 (en) | METHOD OF OBTAINING THERAPEUTIC NANOPARTICLES | |
| DOP2017000013A (en) | PREPARATION PROCEDURE FOR REPLACED 5-FLUORO-1H-PIRAZOLOPIRIDINAS | |
| MX2019006878A (en) | Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug. | |
| EA201591087A1 (en) | NEW BENZIMIDAZOLE DERIVATIVES AS ANTAGONISTS OF EP4 RECEPTOR | |
| GT201400131A (en) | DERIVATIVES OF DIHIDRO-BENZO-OXAZINA AND DIHIDRO-PIRIDO-OXAZINA | |
| EA201590951A1 (en) | DIHYDROPYRAZOL GPR40 MODULATORS | |
| CU24263B1 (en) | DERIVATIVES OF IMIDAZOPIRIDAZINAS INHIBITORS OF QUINASA AKT, USEFUL FOR THE TREATMENT OF CANCER | |
| UY35906A (en) | NEWS DERIVED FROM BENCIMIDAZOL AS LIGANDOS OF EP4 | |
| EA201590954A1 (en) | DIHYDROPYRAZOL GPR40 MODULATORS | |
| EA201590949A1 (en) | DIHYDROPYRAZOL GPR40 MODULATORS | |
| CL2016000436A1 (en) | Method for the treatment of fibrotic disease | |
| UA113962C2 (en) | PHARMACEUTICAL COMPOSITION CONTAINING APOMORPHINE AS AN ACTIVE INGREDIENT | |
| TN2015000120A1 (en) | Oxazolidin-2-one-pyrimidine derivatives | |
| UY34314A (en) | DERIVATIVES OF ANILINA, ITS PREPARATION AND ITS THERAPEUTIC APPLICATION. | |
| UA111333C2 (en) | Method for producing l-arginine salt of perindropryl | |
| MX357763B (en) | Treatment for pancreatic cancer. | |
| UY34543A (en) | DERIVATIVES OF SULFONYLAMINOPIRROLIDINONE, ITS PREPARATION AND THERAPEUTIC APPLICATION. | |
| MX2016002502A (en) | Bendamustine pharmaceutical compositions. | |
| CO2017010018A2 (en) | Derivatives of -2’-vinyl-abscisic acid (s) | |
| PH12017500323A1 (en) | P38 map kinase inhibiting indanyl urea compounds | |
| TR201903234T4 (en) | Pharmaceutical solution containing dopamine for use in the treatment of Parkinson's disease. | |
| CR20170261A (en) | ACID 3- (6-ALCOXI-5-CLORBENZO [D] ISOXAZOL-3-IL) PROPANOIC USEFUL AS QUINURENINE MONOOXIGENASA INHUBERS | |
| BR112015028751A2 (en) | Process for the preparation of 3,5-bis (fluoralkyl) pyrazole derivatives from alpha, alpha-dihaloamines |